Hope after salvage therapy fails: Novel agents for relapsed/refractory hodgkin lymphoma

Research output: Contribution to journalReview article

Abstract

Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However, around 10% to 25% of patients will have primary refractory or relapsed disease, despite using riskadapted strategies. The standard of care for patients with relapsed/refractory Hodgkin lymphoma has been cytoreduction using salvage chemotherapy, followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). Studies have shown that AHSCT produces a durable response rate of 50%, and that patients achieve a complete response with salvage chemotherapy. The outcomes for patients who do not respond to salvage chemotherapy or relapse after an AHSCT have been poor, with a median survival of 25 months. However, with the approval of novel agents over the last decade, the outcomes for patients with relapsed/refractory Hodgkin lymphoma have improved significantly. In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalONCOLOGY (United States)
Volume33
Issue number5
StatePublished - Jan 1 2019

Fingerprint

Salvage Therapy
Hodgkin Disease
Hematopoietic Stem Cell Transplantation
Drug Therapy
Standard of Care
Recurrence
Survival
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hope after salvage therapy fails : Novel agents for relapsed/refractory hodgkin lymphoma. / Kallam, Avyakta; Vose, Julie M.

In: ONCOLOGY (United States), Vol. 33, No. 5, 01.01.2019, p. 192-198.

Research output: Contribution to journalReview article

@article{af1a392b2efe4d319ff415c283800156,
title = "Hope after salvage therapy fails: Novel agents for relapsed/refractory hodgkin lymphoma",
abstract = "Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However, around 10{\%} to 25{\%} of patients will have primary refractory or relapsed disease, despite using riskadapted strategies. The standard of care for patients with relapsed/refractory Hodgkin lymphoma has been cytoreduction using salvage chemotherapy, followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). Studies have shown that AHSCT produces a durable response rate of 50{\%}, and that patients achieve a complete response with salvage chemotherapy. The outcomes for patients who do not respond to salvage chemotherapy or relapse after an AHSCT have been poor, with a median survival of 25 months. However, with the approval of novel agents over the last decade, the outcomes for patients with relapsed/refractory Hodgkin lymphoma have improved significantly. In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.",
author = "Avyakta Kallam and Vose, {Julie M.}",
year = "2019",
month = "1",
day = "1",
language = "English (US)",
volume = "33",
pages = "192--198",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "5",

}

TY - JOUR

T1 - Hope after salvage therapy fails

T2 - Novel agents for relapsed/refractory hodgkin lymphoma

AU - Kallam, Avyakta

AU - Vose, Julie M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However, around 10% to 25% of patients will have primary refractory or relapsed disease, despite using riskadapted strategies. The standard of care for patients with relapsed/refractory Hodgkin lymphoma has been cytoreduction using salvage chemotherapy, followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). Studies have shown that AHSCT produces a durable response rate of 50%, and that patients achieve a complete response with salvage chemotherapy. The outcomes for patients who do not respond to salvage chemotherapy or relapse after an AHSCT have been poor, with a median survival of 25 months. However, with the approval of novel agents over the last decade, the outcomes for patients with relapsed/refractory Hodgkin lymphoma have improved significantly. In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.

AB - Hodgkin lymphoma is a highly curable malignancy, with an excellent prognosis. However, around 10% to 25% of patients will have primary refractory or relapsed disease, despite using riskadapted strategies. The standard of care for patients with relapsed/refractory Hodgkin lymphoma has been cytoreduction using salvage chemotherapy, followed by high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). Studies have shown that AHSCT produces a durable response rate of 50%, and that patients achieve a complete response with salvage chemotherapy. The outcomes for patients who do not respond to salvage chemotherapy or relapse after an AHSCT have been poor, with a median survival of 25 months. However, with the approval of novel agents over the last decade, the outcomes for patients with relapsed/refractory Hodgkin lymphoma have improved significantly. In this article, we present a case of a patient with relapsed Hodgkin lymphoma who responded to salvage chemotherapy incorporating brentuximab vedotin, a novel agent.

UR - http://www.scopus.com/inward/record.url?scp=85069671150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069671150&partnerID=8YFLogxK

M3 - Review article

C2 - 31095720

AN - SCOPUS:85069671150

VL - 33

SP - 192

EP - 198

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 5

ER -